

# Maria Cristina De Martino

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8786261/publications.pdf>

Version: 2024-02-01

29  
papers

1,243  
citations

430754

18  
h-index

501076

28  
g-index

31  
all docs

31  
docs citations

31  
times ranked

1597  
citing authors

#	ARTICLE	IF	CITATIONS
1	ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. <i>European Journal of Endocrinology</i> , 2021, 184, R51-R59.	1.9	11
2	Global epidemiology of acromegaly: a systematic review and meta-analysis. <i>European Journal of Endocrinology</i> , 2021, 185, 251-263.	1.9	33
3	Paediatric Cushing's disease: Epidemiology, pathogenesis, clinical management and outcome. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2021, 22, 817-835.	2.6	23
4	Abnormal linear growth in paediatric adrenal diseases: Pathogenesis, prevalence and management. <i>Clinical Endocrinology</i> , 2020, 92, 98-108.	1.2	20
5	Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials. <i>Frontiers in Endocrinology</i> , 2020, 11, 648.	1.5	72
6	Mitotane Concentrations Influence Outcome in Patients with Advanced Adrenocortical Carcinoma. <i>Cancers</i> , 2020, 12, 740.	1.7	28
7	Vitamin D reverts resistance to the mTOR inhibitor everolimus in hepatocellular carcinoma through the activation of a miR-375/oncogenes circuit. <i>Scientific Reports</i> , 2019, 9, 11695.	1.6	14
8	IGF and mTOR pathway expression and in vitro effects of linsitinib and mTOR inhibitors in adrenocortical cancer. <i>Endocrine</i> , 2019, 64, 673-684.	1.1	23
9	The role of mTOR pathway as target for treatment in adrenocortical cancer. <i>Endocrine Connections</i> , 2019, 8, R144-R156.	0.8	12
10	SUN-358 Dual Release Hydrocortisone as a New Treatment for Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. <i>Journal of the Endocrine Society</i> , 2019, 3, .	0.1	0
11	Effect of combined treatment with a pan-PI3K inhibitor or an isoform-specific PI3K inhibitor and everolimus on cell proliferation in GH-secreting pituitary tumour in an experimental setting. <i>Endocrine</i> , 2018, 62, 663-680.	1.1	9
12	Effects of long-term combined treatment with somatostatin analogues and pegvisomant on cardiac structure and performance in acromegaly. <i>Endocrine</i> , 2017, 55, 872-884.	1.1	36
13	Cushing's disease: the burden of illness. <i>Endocrine</i> , 2017, 56, 10-18.	1.1	136
14	Adrenal Mass: Insight Into Pathogenesis and a Common Link With Insulin Resistance. <i>Endocrinology</i> , 2017, 158, 1527-1532.	1.4	13
15	Effects of the single and combined treatment with dopamine agonist, somatostatin analog and mTOR inhibitors in a human lung carcinoid cell line: an in vitro study. <i>Endocrine</i> , 2017, 56, 603-620.	1.1	14
16	Six controversial issues on subclinical Cushing's syndrome. <i>Endocrine</i> , 2017, 56, 262-266.	1.1	37
17	Metabolic Alterations and Cardiovascular Outcomes of Cortisol Excess. <i>Frontiers of Hormone Research</i> , 2016, 46, 54-65.	1.0	31
18	Comment on Azmahani et al. "Steroidogenic enzymes, their related transcription factors and nuclear receptors in human sebaceous glands under normal and pathological conditions". <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016, 155, 177.	1.2	0

#	ARTICLE	IF	CITATIONS
19	Complications of Cushing's syndrome: state of the art. <i>Lancet Diabetes and Endocrinology</i> , 2016, 4, 611-629.	5.5	371
20	Effects of combination treatment with sirolimus and mitotane on growth of human adrenocortical carcinoma cells. <i>Endocrine</i> , 2016, 52, 664-667.	1.1	8
21	The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 9718-9731.	0.8	19
22	Neuropsychiatric disorders in Cushing's syndrome. <i>Frontiers in Neuroscience</i> , 2015, 9, 129.	1.4	124
23	The treatment with pasireotide in Cushing's disease: effects of long-term treatment on tumor mass in the experience of a single center. <i>Endocrine</i> , 2015, 50, 725-740.	1.1	40
24	Characterization of the mTOR pathway in human normal adrenal and adrenocortical tumors. <i>Endocrine-Related Cancer</i> , 2014, 21, 601-613.	1.6	25
25	How should patients with adrenal incidentalomas be followed up?. <i>Lancet Diabetes and Endocrinology</i> , 2014, 2, 352-354.	5.5	2
26	Pituitary tumors and pregnancy: the interplay between a pathologic condition and a physiologic status. <i>Journal of Endocrinological Investigation</i> , 2014, 37, 99-112.	1.8	34
27	The GH-IGF-SST system in hepatocellular carcinoma: biological and molecular pathogenetic mechanisms and therapeutic targets. <i>Infectious Agents and Cancer</i> , 2014, 9, 27.	1.2	21
28	The role of mTOR inhibitors in the inhibition of growth and cortisol secretion in human adrenocortical carcinoma cells. <i>Endocrine-Related Cancer</i> , 2012, 19, 351-364.	1.6	46
29	Somatostatin and Somatostatin Receptors: from Basic Concepts to Clinical Applications. <i>Progress in Brain Research</i> , 2010, 182, 255-280.	0.9	38